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Introduction. Psoriatic arthritis (APs) is a chronic seronegative inflammatory arthropathy, 
associated with skin psoriasis. Sometimes it can precede the skin psoriatic lesions. Etiology and 
pathogenesis remain unknown, but the genetic predisposition, the influence of the immune 
system and the environment are important in the development of the disease. APs is an 
invalidating disease with a different presentation in time, at one time it predominates as skin 
disease, and another time as articular disease, with erosive and destructive joint changes, which 
is found in about 40-60% of patients. Thus, a complex approach of the clinical features of the 
disease is needed, in order to make a correct and timely diagnosis of the disease.  
Aim of the study. investigation of the evolution of psoriatic arthritis in patients without skin 
psoriasis  
Materials and methods. the study group contains 40 patients diagnosed with psoriatic arthritis 
established in accordance with the CASPAR (2006) diagnostic criteria, admitted to the 
rheumatology and arthrology department of IMSP SCR Timofei Mosneaga during the period 
2015-2017. In order to highlight the evolutionary particularities, the patients were grouped into 2 
groups: I group (30 patients) psoriatic arthritis with skin psoriasis, II group (10 patients) psoriatic 
arthritis without skin psoriasis. Then group I and II were separated into 5 subgroups depending 
on the clinical variant of the disease. The description of each group was made by gender, mean 
age and the average age of joint affection.  
Results. The study performed on a group of 40 patients revealed the clinical particularities of the 
evolutionary variants of psoriatic arthritis, characterized by a wide variety of manifestations of 
the articular syndrome, expressed by 5 clinical types: polyarticular (31 %), axial (25.5%), 
oligoarticular (17.4%), distal interphalangeal (14.5%) and mutilating (11.6%), as well as 
peculiarities of extraarticular disorders.  
Conclusions. Severity of joint damage was assessed in relation to the presence or absence of 
skin manifestations of psoriazis. It has been established that the association of cutaneous 
psoriasis aggravates the clinical evolution of vertebral column lesions, especially in the 
polyarticular variant and less in the axial and mutilating variant.  
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Introduction. Combined therapy, clopidogrel plus aspirin, prevents secondary thrombotic in 
acute coronary syndromes (ACS), after percutaneous coronary interventions (PCI) with 
placement of a coronary artery stent. Clopidogrel is activated in the liver by cytochrome P450 
enzymes. CYP2C19 is the principal enzyme. The most common loss-of-function variant is 
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CYP2C19*2. This contributes to the decrease in the active metabolite of clopidogrel in the blood 
and reduce the effectiveness of clopidogrel therapy.  
Aim of the study. The importance of CYP2C19 genotyping and knowing the patient's 
phenotype. 
Materials and methods. Exploring the bibliographic sources in the years 2010-2017 in the 
databases: PubMed, Google Scholar, Cochrane  
Results. Numerous meta-analyzes have shown that the presence of CYP2C19*2 polymorphism 
in patients administering clopidogrel, increases the risk of cardiovascular (CV) complications 
such as: myocardial infarction (MI), ischemic stroke and stent thrombosis. In March 2010, Food 
and Drug Administration (FDA) recommended genetic testing to determine non-functioning 
CYP2C19 alleles. This test is useful to identify a patient’s CYP2C19 genotype and determines 
the therapeutic course of action. Individualized antiplatelet treatment allows us to anticipate 
potential efficacy, maximize benefits by reducing the risk of recurrent CV events. Studies have 
shown that genotype-guided therapy has economic benefits due to the prevention of adverse 
cardiac events. American College of Cardiology/American Heart Association (2012) 
recommended genetic tests for clopidogrel resistance in patients with recurrent CV events 
despite antiplatelet treatment. The Clinical Pharmacogenetics Implementation Consortium 
(CPIC) (2013) recommend to use genotype-guided antiplatelet therapy for patients with ACS 
who are undergoing PCI and use alternative antiplatelet agent (ticagrelor, prasugrel) for 
intermediate metabolizer (*1/*2; *1/*3; *2/*17) and poor metabilizer (*2/*2; *2/*3; *3/*3), if no 
contraindication.  
Conclusions. CYP2C19 genotyping is useful to identify intermediate and poor metabolizer, 
prescribing an antiplatelet therapy based on CYP2C19 genotype that would reduce thrombotic 
complications. The criteria for personalized therapy have so far not been established that would 
guarantee the efficacy and individual safety of patients that administer clopidogrel. 
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Introduction. Chronic rhinosinusitis is an important public health issue, the incidence and 
prevalence of which has been constantly growing in both the developing and the developed 
countries, having a negative impact on the quality of life and bringing about significant costs for 
the diagnosis and treatment. The management of recurrent ting and chronic rhinosinusitis 
represents a major concern for the otorhinolaryngology service. Traditionally, the treatment of 
recurrent and chronic rhinosinusitis has been performed by administering antibiotics, nasal 
irrigation with saline solution, decongestant nasal sprays, topical and systemic corticosteroids, 
antihistamines, antileukotrienes, and surgery as needed. Unfortunately, these methods are not 
free of risks and adverse effects. At the same time, the efficiency of standard treatment is lower 
than expected.  
Aim of the study. To review the specialized literature and conduct a clinical and immunologic 
research whose aim is treatment of recurrent and chronic rhinosinusitis in children optimization 
using cell therapy.  
Materials and methods. This article summarizes the information from specialized literature 
about the importance of cell therapy in the treatment of a number of pathologies, particularly its 
